Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 7/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | RHOC | P08134 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14283519 | 1.00 | HMGCR (0.53) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL14595549 | 1.00 | HMGCR (0.53) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL14591224 | 0.95 | HMGCR (0.45) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL13694369 | 0.94 | HMGCR (0.52) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL4107689 | 0.93 | HMGCR (0.51) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL4974986 | 0.91 | HMGCR (0.44) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL14283516 | 0.90 | HMGCR (0.45) | HMGCR | |
| SCHEMBL4980328 | 0.88 | HMGCR (0.56) | HMGCRNR1I2ABCB11RHOCCYP3A4 | |
| SCHEMBL13694346 | 0.87 | HMGCR (0.47) | HMGCR | |
| SCHEMBL4107693 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2008-01-24 | — | — | US | disclosed |
| US-7199126-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199126-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199126-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORPORATION (US) | 2007-04-03 | — | — | US | disclosed |
| US-7183285-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORP. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183285-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORP. (US) | 2007-02-27 | — | — | US | disclosed |
| US-7183285-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORP. (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070015779-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7163945-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORP. (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163945-B2 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | PHARMIX CORP. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070004758-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004758-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004758-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | NUMERATE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060084695-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2006-04-20 | — | — | US | disclosed |
| US-20050288306-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050277653-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050272770-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-12-08 | — | — | US | disclosed |
| US-20050261354-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | NUMERATE, INC. | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288306-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 733/4885ABCB11 1752/4885 |
| US-20060084695-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 733/4885ABCB11 1752/4885 |
| US-20050277653-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 733/4885ABCB11 1752/4885 |
| US-20070004758-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 733/4885ABCB11 1752/4885 |
| US-20050261354-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 733/4885ABCB11 1752/4885 |
| US-20070015779-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 734/4885ABCB11 1747/4885 |
| US-20080021054-A1 | COMPOSITIONS AND TREATMENTS FOR INHIBITING KINASE AND/OR HMG-COA REDUCTASE | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 733/4885ABCB11 1752/4885 |
| US-20050272770-A1 | Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase | HMGCR, HMGB3, HMGB2 | HMGCR 1/4885NR1I2 733/4885ABCB11 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.